NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027
Putting Patients First Blog
JULY 2, 2024
The NHC requests more clarity on how CMS will exclude QALY-based metrics and highlight when they have been removed from consideration in MFP justification documentation. Without appropriate guardrails, CMS’ broad definition of drugs eligible for negotiation may discourage these types of improvements. and Keating, N. link] xii Chino, F.,
52 
Let's personalize your content